fadraciclib   Click here for help

GtoPdb Ligand ID: 10461

Synonyms: CYC-065 | CYC065
Compound class: Synthetic organic
Comment: Fadraciclib (CYC065) is a cyclin-dependent kinase 2 and 9 inhibitor that is claimed as compound [1] in patent WO2008122767A2 [2]. Structurally CYC065 is a derivative of seliciclib (CYC202). It was developed by Cyclacel for potential to treat proliferative disorders including cancer, leukemia and psoriasis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 100.78
Molecular weight 397.26
XLogP 3.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(C(O)C)Nc1nc(NCc2cnc(cc2C)C)c2c(n1)n(cn2)C(C)C
Isomeric SMILES CC[C@@H]([C@H](O)C)Nc1nc(NCc2cnc(cc2C)C)c2c(n1)n(cn2)C(C)C
InChI InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
InChI Key DLPIYBKBHMZCJI-WBVHZDCISA-N
No information available.
Summary of Clinical Use Click here for help
CYC065 has advanced to early stage clinical evaluation in leukemia. Click here to link to ClinicalTrials.gov's full list of CYC065 studies.